Gonorrhea is a sexually or vertically transmitted infection secondary to Gram-negative diplococcus Neisseria gonorrhoeae.
It is one of the most common bacterial sexually transmitted infections that may cause pelvic inflammatory disease leading to infertility or ectopic pregnancy.
Most of the infected females are asymptomatic but may present with increased or altered vaginal discharge, dysuria, urethral discharge, abnormal vaginal bleeding, vulval itching or burning, dyspareunia, conjunctivitis and proctitis.
Helpful to confirm compliance of patient with the treatment, ensure resolution of symptoms, inquire about possibility of re-infection, adverse reaction to treatment, or treatment failure and drug resistance, and check on partner notification
Some authorities have recommended that test of cure should be done in all patients with gonococcal infection giving priority to those with persistent signs or symptoms after the treatment and those patients treated with alternative regimens with unknown antimicrobial susceptibility
Test-of-cure should be done 1 week after completion of treatment
Others have recommended test of cure to be done 72 hours after completion of therapy in patients with persistent signs and symptoms or 2 weeks after in asymptomatic patients
Ideally performed with culture or, if not available, with NAAT (2 weeks after treatment) for N gonorrhoeae
Confirmatory culture should be done if NAAT’s result is positive; if culture is positive, phenotypic antimicrobial susceptibility testing should be performed
Pregnant women should be retested 3 months after therapy and during the 3rd trimester if risk for gonococcal infection is high
Culture of relevant specimens and susceptibility testing of N gonorrhoeae should be done in patients who have failed with the recommended treatment regimen and re-treat according to susceptibility results
If treatment failure happened after single therapy, re-treat with dual therapy; if treatment failure happened after dual therapy, re-treat with a dual therapy of higher dose
Patients who had treatment failure with alternative regimens should be treated with Ceftriaxone and Azithromycin and be referred to an infectious disease specialist for further management
Due to the emerging resistance to extended-spectrum cephalosporins in N gonorrhoeae, criteria for probable gonorrhea treatment failure include the following:
Patient with laboratory-confirmed N gonorrhoeae infection and treated with cephalosporin-based regimen and subsequently tested positive for N gonorrhoeae (culture positive ≥72 hours after treatment or NAAT positive ≥7 days after treatment) and without sexual activity following treatment and
Pre- or post-treatment antimicrobial susceptibility testing of N gonorrhoeae isolates showed Ceftriaxone MIC ≥0.125 mcg/mL or Cefixime MIC ≥0.25 mcg/mL
Infections identified after treatment
Typically are due to reinfection which should be distinguished from treatment failure prior to retreatment
Reinfected patients are re-treated with the recommended regimen, sexual abstinence or condom use is reinforced and partner is treated
There may be a need for improved patient education and referral of sex partners
HIV/STI Testing and Counseling
Sexually transmitted infection (STI) consultation allows for an opportunity to discuss patient’s risk factors for STIs and human immunodeficiency virus (HIV)
Determine patient’s risk for HIV and discuss HIV testing
Testing for HIV is recommended and should be offered to all persons seeking evaluation and treatment for STIs
Pretest and post-test counseling, as well as informed consent, are part of the testing procedure
Concomitant infection with HIV may complicate management and control of some STIs
Treatment of gonococcal infection in patients with HIV is similar to patients who are HIV-negative
Gonococcal infection aids in transmission and increases susceptibility to HIV
Evaluation and Treatment of Sex Partners
Sex partners of STI patients may be asymptomatic, thus the importance for partner notification and management
Sex partners of STI patients are likely to be infected and should be offered treatment to prevent further STI transmission and reinfection
All partners who had sexual contact with the patient within 60 days of the diagnosis of infection should be evaluated and treated for both gonococcal and chlamydial infection
If patient’s previous sexual intercourse was >60 days before diagnosis, the latest sexual partner should be evaluated and treated
For patients who present within 14 days of exposure, it is recommended to give epidemiological treatment; for those who present after 14 days of exposure, treat based on testing results
Patients and their sex partners should be instructed to abstain from sexual intercourse until they and their partners have completed the treatment
Continue abstinence x 7 days after a single-dose regimen or until the completion of a 7-day regimen
In situations where concerns exist that the sex partners of a female patient with gonorrhea will not seek treatment, the patient may be the one to deliver therapy to their partners in the form of medication or a prescription
Partner-delivered therapy for gonorrhea should always include treatment for Chlamydia
The approach may not be permitted in some settings
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.